Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 16-Aug-23 6:01 PM View:  | Anderson Glen R. 10% Owner | Indaptus Therapeutics, Inc. (INDP) | 14-Aug-23 | Purchase | 23,934 | $2.34 | $56,005.60 | 2% 1.17M to 1.19M | |
| 16-Aug-23 6:01 PM View: | Anderson Glen R. 10% Owner | Indaptus Therapeutics, Inc. (INDP) | 11-Aug-23 | Purchase | 35,064 | $2.12 | $74,335.70 | 3% 1.13M to 1.17M | |
| 16-Aug-23 6:01 PM View: | Anderson Glen R. 10% Owner | Indaptus Therapeutics, Inc. (INDP) | 10-Aug-23 | Private Purchase | 44,354 | $1.94 | $86,046.80 | 4% 1.09M to 1.13M | |
| 19-Dec-22 9:06 PM View: | Litchev Boyan Vesselinov Chief Medical Officer | Indaptus Therapeutics, Inc. (INDP) | 01-Dec-22 | Purchase | 500 | $1.87 | $935.45 | 77% 0.65K to 1.15K | |
| 19-Dec-22 9:06 PM View: | Litchev Boyan Vesselinov Chief Medical Officer | Indaptus Therapeutics, Inc. (INDP) | 22-Nov-22 | Purchase | 500 | $1.83 | $915.00 | 333% 0.15K to 0.65K | |
| 22-Nov-22 8:00 AM View: | Meckler Jeffrey A CEO and Director Director | Indaptus Therapeutics, Inc. (INDP) | 21-Nov-22 | Purchase | 9,600 | $1.90 | $18,240.00 | 15% 65.77K to 75.37K | |
| 22-Nov-22 8:00 AM View: | Meckler Jeffrey A CEO and Director Director | Indaptus Therapeutics, Inc. (INDP) | 18-Nov-22 | Private Purchase | 400 | $1.76 | $705.48 | < 1% 65.37K to 65.77K | |
| 12-Sep-22 9:00 AM View: | Meckler Jeffrey A CEO and Director Director | Indaptus Therapeutics, Inc. (INDP) | 08-Sep-22 | Private Purchase | 10,308 | $2.80 | $28,862.40 | 19% 55.07K to 65.37K | |
| 08-Sep-22 9:00 AM View: | Meckler Jeffrey A CEO and Director Director | Indaptus Therapeutics, Inc. (INDP) | 07-Sep-22 | Purchase | 8,632 | $2.57 | $22,184.20 | 19% 46.43K to 55.07K | |
| 09-Sep-22 9:00 AM View: | Linscott Walt Addison Chief Business Officer | Indaptus Therapeutics, Inc. (INDP) | 07-Sep-22 | Private Purchase | 150 | $2.62 | $393.00 | 100% 0 to 0.15K | |
| 08-Sep-22 9:00 AM View: | Meckler Jeffrey A CEO and Director Director | Indaptus Therapeutics, Inc. (INDP) | 06-Sep-22 | Private Purchase | 1,060 | $2.44 | $2,586.40 | 2% 45.37K to 46.43K | |
| 07-Jun-22 8:00 AM View: | Meckler Jeffrey A CEO and Director Director | Indaptus Therapeutics, Inc. (INDP) | 06-Jun-22 | Private Purchase | 19,727 | $2.63 | $51,882.00 | 77% 25.65K to 45.37K | |
| 19-Dec-22 9:06 PM View: | Litchev Boyan Vesselinov Chief Medical Officer | Indaptus Therapeutics, Inc. (INDP) | 02-Mar-22 | Purchase | 50 | $4.09 | $204.63 | 50% 100 to 0.15K | |
| 02-Feb-22 5:08 PM View: | Newman Michael James CSO and Director Director 10% Owner | Indaptus Therapeutics, Inc. (INDP) | 01-Feb-22 | Market Sale (Planned) | 14,130 | $5.00 | $70,692.40 | (< 1%) 2.76M to 2.75M | (6%) |
| 19-Dec-22 9:06 PM View: | Litchev Boyan Vesselinov Chief Medical Officer | Indaptus Therapeutics, Inc. (INDP) | 31-Jan-22 | Private Purchase | 100 | $4.65 | $465.00 | 100% 0 to 100 | |
| 02-Feb-22 5:08 PM View: | Newman Michael James CSO and Director Director 10% Owner | Indaptus Therapeutics, Inc. (INDP) | 31-Jan-22 | Market Sale (Planned) | 5,870 | $5.00 | $29,350.60 | (< 1%) 2.77M to 2.76M | (6%) |
| 19-Nov-21 9:16 AM View: | Meckler Jeffrey A CEO and Director Director | Indaptus Therapeutics, Inc. (INDP) | 18-Nov-21 | Market Purchase | 11,187 | $5.82 | $65,108.30 | 77% 14.46K to 25.65K | |
| 16-Sep-21 6:22 PM View: | Meckler Jeffrey A CEO and Director Director | Indaptus Therapeutics, Inc. (INDP) | 14-Sep-21 | Market Purchase | 12,000 | $7.00 | $84,000.00 | 488% 2.46K to 14.46K | 54% |
